Development of a pentavalent broadly protective nucleoside-modified mRNA vaccine against influenza B viruses

Pardi, Norbert and Carreno, Juan Manuel and O'Dell, George and Tan, Jessica and Bajusz, Csaba (2022) Development of a pentavalent broadly protective nucleoside-modified mRNA vaccine against influenza B viruses. NATURE COMMUNICATIONS, 13 (1). ISSN 2041-1723

Preview

Text s41467-022-32149-8.pdf Available under License Creative Commons Attribution. Download (3MB) | Preview

Abstract

Messenger RNA (mRNA) vaccines represent a new, effective vaccine platform with high capacity for rapid development. Generation of a universal influenza virus vaccine with the potential to elicit long-lasting, broadly cross-reactive immune responses is a necessity for reducing influenza-associated morbidity and mortality. Here we focus on the development of a universal influenza B virus vaccine based on the lipid nanoparticle-encapsulated nucleoside-modified mRNA (mRNA-LNP) platform. We evaluate vaccine candidates based on different target antigens that afford protection against challenge with ancestral and recent influenza B viruses from both antigenic lineages. A pentavalent vaccine combining all tested antigens protects mice from morbidity at a very low dose of 50 ng per antigen after a single vaccination. These findings support the further advancement of nucleoside-modified mRNA-LNPs expressing multiple conserved antigens as universal influenza virus vaccine candidates.

Actions (login required)

Edit Item